TYBOST

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug TYBOST contains one active pharmaceutical ingredient (API):

1	Cobicistat UNII LW2E03M5PG - COBICISTAT
	Cobicistat is a mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.
	Read more about Cobicistat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TYBOST Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AX03		V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AX Other therapeutic products
Discover more medicines within V03AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1626511, 1626522
ES	Centro de información online de medicamentos de la AEMPS	113872001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	426384
FR	Base de données publique des médicaments	65434539
GB	Medicines & Healthcare Products Regulatory Agency	239733
IT	Agenzia del Farmaco	043032010, 043032022
LT	Valstybinė vaistų kontrolės tarnyba	1071513, 1071514
NL	Z-Index G-Standaard, PRK	116904
PL	Rejestru Produktów Leczniczych	100315114
US	FDA, National Drug Code	61958-1401